Our group's subsequent work after Jupiter-06 study (Cancer Cell, 2022). #Cancer #Immunotherapy

Dr Yuan presented our team's recent phase 2 trial of chemo w/wo toripalimab in the perioperative setting of gastric cancer. #ASCO23 ASCO

Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis - read more from Feng Wang & researchers from Sun Yat-sen University Cancer Center Cell Reports Medicine #ASCO23 hubs.li/Q01RP-rV0

Dr Xu，our president, team leader and the leading PI , has updated the GLOW study in ASCO. #ASCO23 #Gastroenterology

Enjoy ASCO and meeting old friends! Kai-Keen Shiu Scott Kopetz

Our phase 3 study GLOW was published recently by Nature Medicine. Another standard therapy for advanced gastric cancer patients with positive Claudin18.2. Kohei shitara Saheli Sadanand #asco

I am honored to present the results of our investigator initiated phase 2 trial (Capability-01) in the ESMO meeting. A phase 3 is ongoing. #cancer #Immunotherapy

I am horned to present the results of AdvanTIG-203, a multi-center international trial of PD-1 with TIGIT antibody as 2nd line for ESCC and enjoyed the section with all excellent speakers. #cancer #Immunotherapy #ESMO23

Great experiences in ESMO. Our medical oncology team of Gastrointestinal cancer in Sun Yat-sen University Cancer Center had 6 oral presentations including 2 presented by me. It's always inspiring and exciting to meet the brilliant minds around the world. #ESMO23 #oncology #cancer

Our gastric cancer MDT group's work was just published. Chemo plus PD-1 antibody resulted in a pCR rate of 21%. Nature Medicine GastricCancer

Excited to share my recent work published in Nature Communications with the title "Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer." dlvr.it/T2z83z #MachineLearning #CancerGenomics 📚🔬

The Capability-01 trial was just published. The combination of HADCi, anti-PD-1 and anti-VEGF achieved an ORR of 44% with a mPFS 7.3 mos in MSS mCRC patients. Thanks to the study team, all patients and family. #colorectalcancer #Immunology #Cancer Nature Medicine

In a phase 2 trial comparing anti-PD-1 + anti-VEGF + HDAC inhibitor vs. anti-PD-1 + HDAC inhibitor in patients with MSS/pMMR #ColorectalCancer, the triplet combo leads to better 18 week progression-free survival. #ColorectalCancerAwarenessMonth nature.com/articles/s4159…

Thanks to Cell for inviting us to write this commentary. Challenges and opportunities in oncology drug development and clinical research in China: Cell cell.com/cell/fulltext/… Cell

Now at #ASCO24: In the phase 3 FRUTIGA trial, the multi anti-VEGFR inhibitor #fruquintinib + chemotherapy significantly extended progression-free survival, but not overall survival, as 2L therapy in patients with advanced #GastricCancer or #GEJCancer doi.org/10.1038/s41591…

Having fun at ASCO and meeting old friends. #ASCO24

It's always great to meet old friends and make new friends in ASCO.

Our preview of two very interesting papers. One from Dr Bardelli's lab, the other from Dr Diaz's group. Bardelli Lab Luis Diaz Cancer Cell